Lowenstein, P., A Orringer, D., Sagher, O., Heth, J., Hervey-Jumper, S., Gerald Mammoser, A., Junck, L., Leung, D., Umemura, Y., Steven Lawrence, T., Miran Kim, M., Richard Wahl, D., McKeever, P., Ines Camelo-Piragua, S., Lieberman, A., Venneti, S., Comba, A., Altshuler, D., M Muraszko, K., & Castro, M. (n.d.). aTIM-44. A PHASE I FIRST-IN-HUMAN TRIAL OF TWO ADENOVIRAL VECTORS EXPRESSING HSV1-TK AND FLT3L FOR TREATING NEWLY DIAGNOSED RESECTABLE MALIGNANT GLIOMA: THERAPEUTIC REPROGRAMMING OF THE BRAIN IMMUNE SYSTEM. Neuro-oncology, 21, vi11. http://access.bl.uk/ark:/81055/vdc_100101668512.0x000033